{
  "title": "Supplemental New Drug Application  ",
  "outline": [
    {
      "level": "H2",
      "text": "NDA (Serial Number)",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Sponsor:",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Drug:",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Proposed Indication:",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Material Submitted:",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Correspondence Date:",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Date Received / Agency:",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Date Review Completed",
      "page": 1
    },
    {
      "level": "H3",
      "text": "Reviewer:",
      "page": 1
    },
    {
      "level": "H1",
      "text": "TABLE OF CONTENTS",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Executive Summary",
      "page": 3
    },
    {
      "level": "H3",
      "text": "Recommendation",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Proposed Indication",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Summary Of Clinical Findings",
      "page": 3
    },
    {
      "level": "H2",
      "text": "Conclusions",
      "page": 6
    },
    {
      "level": "H1",
      "text": "1. Background",
      "page": 7
    },
    {
      "level": "H1",
      "text": "2. Contents Of Submission",
      "page": 7
    },
    {
      "level": "H1",
      "text": "3. Contents Of Review",
      "page": 8
    },
    {
      "level": "H1",
      "text": "4. Key Diagnostic Instruments Used in Efficacy Study (Study",
      "page": 9
    },
    {
      "level": "H1",
      "text": "2311)",
      "page": 9
    },
    {
      "level": "H2",
      "text": "4.1 UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria",
      "page": 9
    },
    {
      "level": "H3",
      "text": "For Parkinson’s Disease",
      "page": 9
    },
    {
      "level": "H2",
      "text": "Step 1 Diagnosis of Parkinsonian syndrome",
      "page": 9
    },
    {
      "level": "H3",
      "text": "Step 2 Exclusion criteria for Parkinson’s disease",
      "page": 9
    },
    {
      "level": "H3",
      "text": "Step 3 Supportive prospective positive criteria for Parkinson’s disease",
      "page": 9
    },
    {
      "level": "H3",
      "text": "(Three or more required for diagnosis of definite Parkinson’s disease)",
      "page": 9
    },
    {
      "level": "H2",
      "text": "4.2 DSM-IV Criteria For Dementia Due To Parkinson’s Disease",
      "page": 10
    },
    {
      "level": "H1",
      "text": "5. Efficacy Outcome Measures And Selected Additional",
      "page": 10
    },
    {
      "level": "H1",
      "text": "Instruments Used In Efficacy Study",
      "page": 10
    },
    {
      "level": "H2",
      "text": "5.1 Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-",
      "page": 10
    },
    {
      "level": "H3",
      "text": "Cog)",
      "page": 10
    },
    {
      "level": "H2",
      "text": "5.2 Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression",
      "page": 10
    },
    {
      "level": "H3",
      "text": "Of Change (ADCS-CGIC)",
      "page": 10
    },
    {
      "level": "H2",
      "text": "5.3 Alzheimer’s Disease Cooperative Study – Activities Of Daily Living",
      "page": 11
    },
    {
      "level": "H3",
      "text": "Scale (ADCS-ADL)",
      "page": 11
    },
    {
      "level": "H2",
      "text": "5.4 Cognitive Drug Research Computerized Assessment System",
      "page": 11
    },
    {
      "level": "H2",
      "text": "5.5 Delis-Kaplan Executive Functioning System (D-KEFS) Test Battery",
      "page": 12
    },
    {
      "level": "H3",
      "text": "Test",
      "page": 13
    },
    {
      "level": "H2",
      "text": "5.6 Mini-Mental Status Examination",
      "page": 13
    },
    {
      "level": "H2",
      "text": "5.7 Neuropsychiatry Inventory",
      "page": 13
    },
    {
      "level": "H2",
      "text": "5.8 Ten-Point Clock Test",
      "page": 13
    },
    {
      "level": "H2",
      "text": "5.9 Symbol-Digit Modalities Test",
      "page": 14
    },
    {
      "level": "H2",
      "text": "5.10 Health Economic Parameters",
      "page": 14
    },
    {
      "level": "H2",
      "text": "5.11 Unified Parkinson’s Disease Rating Scale (UPDRS)",
      "page": 14
    },
    {
      "level": "H1",
      "text": "6. Summary Of Key Efficacy Study (EXPRESS Study; Study",
      "page": 15
    },
    {
      "level": "H1",
      "text": "2311)",
      "page": 15
    },
    {
      "level": "H2",
      "text": "6.1 Outline",
      "page": 15
    },
    {
      "level": "H2",
      "text": "6.2 Results Of Primary Efficacy Analysis",
      "page": 15
    },
    {
      "level": "H1",
      "text": "7. Description Of Efficacy Study 2311 (EXPRESS Study)",
      "page": 16
    },
    {
      "level": "H2",
      "text": "7.1 Protocol",
      "page": 16
    },
    {
      "level": "H3",
      "text": "The protocol described below is the final version",
      "page": 16
    },
    {
      "level": "H2",
      "text": "Note that brain imaging (i.e., computerized tomography or magnetic",
      "page": 21
    },
    {
      "level": "H3",
      "text": "resonance scanning) was not required prior to entry into the study.",
      "page": 21
    },
    {
      "level": "H2",
      "text": "7.2 Study Results",
      "page": 27
    },
    {
      "level": "H2",
      "text": "7.3 Sponsor’s Conclusions",
      "page": 45
    },
    {
      "level": "H2",
      "text": "7.4 Study Abstract",
      "page": 46
    },
    {
      "level": "H2",
      "text": "7.5 Additional Observations And Comments By Agency Statistical",
      "page": 47
    },
    {
      "level": "H3",
      "text": "Reviewer About Study 2311",
      "page": 47
    },
    {
      "level": "H2",
      "text": "7.6 Reviewer’s Comments",
      "page": 49
    },
    {
      "level": "H1",
      "text": "8. Study 2311E1 (Open-Label Uncontrolled Extension To Study",
      "page": 50
    },
    {
      "level": "H1",
      "text": "2311)",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.1 Protocol 2311E1",
      "page": 50
    },
    {
      "level": "H2",
      "text": "8.2 Safety Results Of Study 2311E1",
      "page": 52
    },
    {
      "level": "H2",
      "text": "8.3 Sponsor’s Conclusions Regarding Safety",
      "page": 56
    },
    {
      "level": "H2",
      "text": "8.4 Reviewer’s Comments",
      "page": 56
    },
    {
      "level": "H1",
      "text": "9. Study 2314 (Non-Interventional Validation Study)",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.1 Protocol",
      "page": 57
    },
    {
      "level": "H2",
      "text": "9.2 Main Results",
      "page": 60
    },
    {
      "level": "H2",
      "text": "9.3 Sponsor’s Conclusions",
      "page": 66
    },
    {
      "level": "H1",
      "text": "10. Summary Of Earlier Meeting Between Division And Sponsor",
      "page": 67
    },
    {
      "level": "H1",
      "text": "Regarding This Application.",
      "page": 67
    },
    {
      "level": "H1",
      "text": "11. Sponsor’s Current View Of Dementia Associated With",
      "page": 69
    },
    {
      "level": "H1",
      "text": "Parkinson’s Disease, And Appropriateness Of ADAS-Cog And",
      "page": 69
    },
    {
      "level": "H1",
      "text": "ADCS-ADL In Evaluating Treatment Effects In Dementia",
      "page": 69
    },
    {
      "level": "H1",
      "text": "Associated With Parkinson’s Disease",
      "page": 69
    },
    {
      "level": "H2",
      "text": "11.1 Dementia Associated With Parkinson’s Disease (Expert Report:",
      "page": 69
    },
    {
      "level": "H3",
      "text": "Diagnosing Dementia Associated With Parkinson’s Disease And",
      "page": 69
    },
    {
      "level": "H3",
      "text": "Distinguishing It From Alzheimer’s Disease)",
      "page": 69
    },
    {
      "level": "H3",
      "text": "Neuropsychological Domain",
      "page": 73
    },
    {
      "level": "H3",
      "text": "Non-Cognitive Feature",
      "page": 73
    },
    {
      "level": "H2",
      "text": "11.2 Appropriateness Of Using The ADAS-Cog And ADCS-ADL As",
      "page": 74
    },
    {
      "level": "H3",
      "text": "Outcome Measures In Dementia Associated With Parkinson’s Disease",
      "page": 74
    },
    {
      "level": "H1",
      "text": "12. Financial Disclosure Certification",
      "page": 77
    },
    {
      "level": "H2",
      "text": "12.1 Components Of Certification",
      "page": 77
    },
    {
      "level": "H2",
      "text": "12.2 Reviewer’s Comments",
      "page": 77
    },
    {
      "level": "H1",
      "text": "13. Site Inspection Report",
      "page": 77
    },
    {
      "level": "H1",
      "text": "14. Review Of Proposed Labeling",
      "page": 78
    },
    {
      "level": "H1",
      "text": "15. Comments",
      "page": 78
    },
    {
      "level": "H2",
      "text": "15.1 General",
      "page": 78
    },
    {
      "level": "H2",
      "text": "15.2 Efficacy",
      "page": 78
    },
    {
      "level": "H3",
      "text": "context of  this application is whether the results of Study 2311 establish",
      "page": 81
    },
    {
      "level": "H3",
      "text": "that Exelon® is effective in the treatment of an entity (dementia associated",
      "page": 81
    },
    {
      "level": "H3",
      "text": "with Parkinson’s Disease [Parkinson’s Disease Dementia]) that is",
      "page": 81
    },
    {
      "level": "H3",
      "text": "sufficiently distinct from mild to moderate dementia of the Alzheimer’s type",
      "page": 81
    },
    {
      "level": "H3",
      "text": "[for the treatment of which Exelon® is already approved] to justify a",
      "page": 81
    },
    {
      "level": "H3",
      "text": "separate regulatory claim.",
      "page": 81
    },
    {
      "level": "H3",
      "text": "Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229-37",
      "page": 92
    },
    {
      "level": "H2",
      "text": "15.3 Safety",
      "page": 92
    },
    {
      "level": "H1",
      "text": "16. Conclusions",
      "page": 93
    },
    {
      "level": "H1",
      "text": "17. Recommendation",
      "page": 93
    }
  ]
}